$BSX

Boston Scientific faces class action lawsuit alleging material misstatements about electrophysiology growth. Stock fell 17.6% after disclosing slower market growth and competitive pressures.

Boston Scientific faces class action over false electrophysiology segment statements. Investors from July 2025–February 2026 may recover damages; lead plaintiff deadline May 4, 2026.

Securities lawsuit alleges $BSX made false statements about electrophysiology sustainability. Investors who bought stock July 2025-February 2026 may qualify for compensation.

Boston Scientific faces class action lawsuit after 17% stock decline following $0.45 EPS miss versus $0.48-$0.52 guidance, amid alleged undisclosed Electrophysiology market share losses.

Class action lawsuit alleges Boston Scientific made false statements about U.S. electrophysiology segment sustainability, citing undisclosed competitive pressures and regulatory headwinds affecting procedure volumes.

Robbins Geller launches class action lawsuit against $SNOW, alleging securities fraud over false product efficiency claims and material business disclosures between June 2023 and February 2024.

Three companies face class action lawsuits alleging securities fraud. Boston Scientific stock fell 17% after missing earnings guidance amid alleged false revenue projections.

Class action filed against $BSX alleging executives misrepresented U.S. electrophysiology segment sustainability. Claims executives concealed adverse trends, competitive pressures, regulatory challenges.

Law firm investigates $BSC for allegedly misleading investors about U.S. Electrophysiology growth sustainability and competitive pressures during July 2025-February 2026 period.

Rosen Law Firm sued $ENPH for allegedly misleading investors on inventory management and financial prospects amid tax credit concerns.

Rosen Law Firm files class action against $BSX over alleged false statements regarding U.S. Electrophysiology segment sustainability and concealed adverse facts.

Boston Scientific faces class action lawsuit alleging misleading statements about electrophysiology market position, with stock down 17% after missing earnings guidance.

Class action lawsuit filed against $BSX alleging executives made false statements about U.S. electrophysiology segment sustainability, concealing competitive pressures and regulatory headwinds.

Rosen Law Firm files class action against $BSX over alleged false statements regarding U.S. Electrophysiology segment sustainability, resulting in earnings miss and weak guidance.

Class action lawsuit filed against $BSX over alleged misrepresentations in U.S. electrophysiology segment between July 2025 and February 2026.

Law firm Levi & Korsinsky files class action against Boston Scientific, citing misleading statements. Stock tumbled 17.6% after disappointing Q4 2025 earnings and weak 2026 guidance.

Boston Scientific positioned to capitalize on global aging through AFib, chronic pain, and Parkinson's treatments; recent acquisitions boost stroke capabilities.

Boston Scientific faces securities fraud investigation after 17.6% stock drop triggered by weaker-than-expected electrophysiology division sales in Q4 2025 results.

Boston Scientific suspended AXIOS Stent devices after 167 serious adverse events and three deaths linked to deployment failures. FDA directed healthcare facilities to stop using affected devices.

Neuromodulation device market expected to double to $16.1 billion by 2032, driven by rising neurological diseases, technological advances, and regulatory support.